Ken Griffin's position in Sarepta Therapeutics is currently worth $5.49 Million. That's 0.01% of their equity portfolio (1527th largest holding). The first Sarepta Therapeutics trade was made in Q2 2013. Since then Ken Griffin bought shares 56 more times and sold shares on 53 occasions. The investor's estimated purchase price is $12.2 Million, resulting in a loss of 55%.